Navigation Links
Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
Date:10/12/2010

ANN ARBOR, Mich., Oct. 12 /PRNewswire/ -- Incept BioSystems, Inc. ("Incept"), a privately-held biomedical device company using patented, microfluidic technology developed at the University of Michigan, announced today the completion of the first U.S. human clinical trial of its proprietary, SMART Start Embryo Culture System, and the recent submission of a 510(k) application to the U.S. Food & Drug Administration ("FDA").  A decision as to market clearance for the device is expected from the FDA sometime in 2011.

As compared with the current in vitro fertilization ("IVF") practice of culturing embryos in a static environment (i.e. a microdrop in a culture dish), Incept's SMART Start Embryo Culture System is a device that enables a continuous, refreshable culture microenvironment while using industry-standard IVF culture medium.

The objective of the clinical trial, for patients undergoing IVF, was to assess the impact on a) morphological embryo development (structural characteristics), and b) embryo survival rates, when embryos are subjected to a refreshable culture microenvironment. A total of 496 embryos from 36 couples who were diagnosed with infertility, and were planning to undergo IVF and embryo transfer, were enrolled in the prospective, randomized performance study, which took place at four investigational sites. Data from the study (P=0.0145) showed that Incept's SMART Start Embryo Culture System met the primary endpoint and was non-inferior to the conventional static dish culture, based on the number of embryos that reached the 8-cell stage at 72 hours of culture.

Commenting on today's news, Christopher Bleck, President and Chief Executive Officer of Incept, noted, "We are pleased with the trial results, which confirmed the safety of the SMART Start Embryo Culture System. This is the first time that any microfluidic technology has been used successfully to help treat infertility patients and is, therefore,
'/>"/>

SOURCE Incept BioSystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
2. Biosystems International Merges With Microbiochips
3. NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group
4. NEXUS Biosystems Acquires Tecan Groups REMP Sample Management Business
5. InfraReDx Completes $21 Million Equity Financing
6. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
7. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
8. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
9. DiFUSION Technologies Completes Successful Antimicrobial Implant Animal Trial
10. IDEV Technologies Completes $46 Million Preferred Stock Financing With Piper Jaffray and Additional Strategic Investor
11. SAFC® Completes Expansion of High-Potency Fermentation Capabilities at Israel Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... , September 18, 2014 After 6 ... community, we,re finally here - the new programme for the ... 2015, part of our global Cool Chain series, has just ... here ! As the lines between supply chain, ... together a programme that is broad and yet specific, focused ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... Becomes Squarer, Makes You Look Older, ASPS,Study Reveals, ... giving away your age, and it has nothing to ... in January,s Plastic and,Reconstructive Surgery(R) (PRS), the official medical ... that as we age, the,lower jaw continues to grow, ...
... Inc.,today announced that a paper published in ... reports that SF1126, the company,s lead product,candidate, ... paper, entitled "A Vascular Targeted Pan Phosphoinositide ... Activity," is,based on preclinical studies conducted by ...
Cached Medicine Technology:Looking Older? How Square is Your Jaw Line? 2Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... antidepressant can quickly alter the way brain cells communicate with ... Sept. 18 in Current Biology , are a ... antidepressants. Experts said the hope is to eventually be able ... from a drug -- and which people would fare better ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... convene a one-day conference at the Milken Institute School ... September 25, 2014 to discuss the Global Health Security ... purpose of this event is to invite discussion of ... years, including action plans to curtail the current deadly ... GHSA, international organizations and more than 50 countries have ...
(Date:9/18/2014)... N.C. Dangerous new pathogens such as the Ebola ... ancient scourges such as the bubonic plague are still ... responds to infections. , In a study published online ... researchers at Duke Medicine and Duke-NUS Graduate Medical School ... bubonic plague hitchhike on immune cells in the lymph ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2
... Orissa government has ordered administrations of all 30 districts to ... three days.// ,The officials were Thursday asked to ... senior health department official. ,These would then be ... government does not have testing facilities to confirm the presence ...
... safety lawyer, writes about why it is essential for us ... that there is a major defect in the food safety ... people affected or even killed by contaminated food products from ... it prevents our society from knowing the source of our ...
... of NSAID by women in their first trimester could ... ,Non-steroidal anti-inflammatory drugs, NSAIDs, Cardiac septal defects, Journal ... Congenital abnormality, Diabetes ,Women who take non-steroidal ... more likely to give birth to babies with congenital ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... hundreds of resident doctors in Delhi who had gone on ... agitation //for the next three months with the reservation bill ... the parliament has referred the reservation bill to the standing ... being. The bill will be placed in the floor of ...
... the University of Pennsylvania have disclosed that a specific ... of changing into bone, muscle, neurons or other// types ... environment. , ,The researchers found that ... bone marrow, are soliciting tangible clues from their local ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Medicine Products: